Clinical Trials Logo

Clinical Trial Summary

The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer


Clinical Trial Description

The study is a multicenter, prospective clinical study, expected to include subjects who visited the selected research center from April 2024 to March 2026, underwent radical tumor resection surgery, and were pathologically diagnosed with pancreatic adenocarcinoma. The subjects are divided into two groups. One group is the standard chemotherapy group, with a planned inclusion of no less than 428 subjects. The chemotherapy will be treated using the Class 1A chemotherapy regimen recommended by the 2022 version of the CSCO guidelines; One group is the Huaier treatment group, with a planned inclusion of no less than 214 subjects. All subjects voluntarily give up the postoperative adjuvant treatment recommended by the guidelines and only choose Huaier granules for postoperative adjuvant treatment. A total of no less than 642 subjects are planned to be included. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06368063
Study type Interventional
Source Health Science Center of Xi'an Jiaotong University
Contact Zheng Wang, PhD
Phone +8615902993665
Email zheng.wang11@mail.xjtu.edu.cn
Status Recruiting
Phase Phase 4
Start date May 6, 2024
Completion date March 2028

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06375928 - EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) N/A
Recruiting NCT06388967 - Pancreatic Cancer Detection Consortium
Completed NCT05483257 - Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Recruiting NCT05287165 - Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms Early Phase 1
Not yet recruiting NCT06287749 - French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04736043 - Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid
Completed NCT04224402 - Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. Phase 2
Terminated NCT03344172 - Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer Phase 2
Not yet recruiting NCT05479708 - ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Not yet recruiting NCT05637567 - Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head Phase 2
Recruiting NCT05181605 - Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors Phase 2/Phase 3